Local aerospace firm lands $2.5M for ‘state-of-the-art’ 3D printer
The Cornerstone Research Group will receive a $2.5 million award to enhance aerospace manufacturing through the use of a ...
As Trump’s Trade War Unfolds, American Companies Brace for Pain
American companies intent on making goods in the United States are fretting over the impact of tariffs on their access to ...
Court oversight ordered for abandoned hospital in victory for city of Dallas, neighbors
A Dallas County judge ordered the former Tri-City Hospital into receivership Monday after city lawyers said the site had ...
SouthBMore1d
Clyde’s Restaurant Group Opening Event and Wedding Venue at Baltimore Peninsula
Today, the Baltimore Peninsula development team announced it has signed a new 9,000 sq. ft. lease with Clyde’s Restaurant ...
WYSO6d
How a Dayton research group is working to prevent frostbite for the military
Cornerstone Research Group has developed heated boot liners that autonomously activate in temperatures as low as minus 49 ...
techexplorist6d
Hubble sees a rare ‘bullseye’ galaxy with nine mesmerizing rings
Astronomers have discovered a unique collisional ring galaxy, nicknamed the "Bullseye," that features nine rings, the most ...
grmdaily.com4d
‘HC Pod’ talk ‘CRG’, Potter Payper & more in new episode
Chuckie and Poet are back with a new edition of HC Pod, as they discuss the week's hot topics, including Central Cee's CRG album release.
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...
Truist cuts Cargo Therapeutics rating, slashes PT to $7
Truist Securities revised its position on Cargo Therapeutics (NASDAQ:CRGX), currently trading at $13.19 with a market ...
The Western Producer11d
Sprayer modifications that work
Glacier FarmMedia - From cheap plastic pails to aftermarket tech, sprayer operators find a variety of ways to improve how ...
Cargo Therapeutics to discontinue FIRCE-1 Phase 2 study of Firi-cel
CARGO Therapeutic announced that it has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 ...